NEW YORK (GenomeWeb News) — Genetix last week said it has completed its acquisition of Applied Imaging.
 
Genetix plans to use the company’s protein biomarker hardware and software with its own ClonePix and CloneSelect Imager and reagents to “track the progress of drug discovery” from lab to clinic.
 
Applied Imaging’s Ariol instruments and CytoVision software are used to study tumors at the protein biomarker level to find targets, monitor responses, and predict the how a drug will work.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.